Does antiviral therapy have a role in the control of Japanese encephalitis?

Antiviral Research

Volumn 78, Issue 1, 2008, Pages 140-149

  Gould, E A ^a,b   Solomon, T ^c   Mackenzie, J S ^d  

^a Aix Marseille University IRD 190 Inserm 1207   (France)

^b CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

^c School of Tropical Medicine   (United Kingdom)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

Antiviral therapy; Antivirals; Control strategies; Japanese encephalitis; Japanese encephalitis virus

Indexed keywords

2 THIOAZAURIDINE; 6 AZAURIDINE ACETATE; ALPHA2A INTERFERON; AZAURIDINE DERIVATIVE; CHIMERIVAX JE; COMPLEMENTARY RNA; DEXAMETHASONE; ENZYME INHIBITOR; IMMUNOGLOBULIN; INOSINATE DEHYDROGENASE INHIBITOR; INTERFERON; JAPANESE ENCEPHALITIS VACCINE; JAPANESE ENCEPHALITIS VIRUS ANTIBODY; LENTIVIRUS VECTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PIRAZOFURIN; PRASTERONE; RIBAVIRIN; SA 14 42; SALICYLATE SODIUM; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; CLIMATE CHANGE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DEFORESTATION; DISEASE PREDISPOSITION; DRUG MEGADOSE; EPIDEMIC ENCEPHALITIS; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION CONTROL; INFECTION RISK; IRRIGATION (AGRICULTURE); JAPANESE ENCEPHALITIS VIRUS; MIGRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS REPLICATION;

AGED; ANIMALS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS;

ANIMALIA; AVES; JAPANESE ENCEPHALITIS VIRUS;

EID: 40749116583     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.10.005     Document Type: Article

References (134)

1. Acambis, 2007. Acambis ChimeriVax™-JE: a single-dose JE vaccine for endemic markets and travellers. www.acambis.co.uk/default.asp?id=936.
2. Adelman Z.N., Sanchez-Vargas I., Travanty E.A., Carlson J.O., Beaty B.J., Blair C.D., and Olson K.E. RNA silencing of dengue virus type 2 replication in transformed C6/36 mosquito cells transcribing an inverted-repeat RNA derived from the virus genome. J. Virol. 76 (2002) 12925-12933
3. Anderson J.F., and Rahah J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg. Infect. Dis. 8 (2002) 107-108
4. Appaiahgari M.B., and Vrati S. DNAzyme-mediated Inhibition of Japanese encephalitis virus replication in mouse brain. Mol. Ther. 9 (2007) 1593-1599
5. Barrett A.D. Japanese encephalitis and dengue vaccines. Biologicals 25 (1997) 27-34
6. Ben-Nathan D., Lustig S., Tam G., Robinzon S., Segal S., and Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188 (2003) 5-12
7. Benenson M.W., Top Jr. F.H., Gresso W., Ames C.W., and Altstatt L.B. The virulence to man of Japanese encephalitis virus in Thailand. Am. J. Trop. Med. Hyg. 24 (1975) 974-980
8. Benvegnu L., Chemello L., Noventa F., Fattovich G., Pontisso P., and Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83 (1998) 901-909
9. Best S.M., Morris K.L., Shannon J.G., Robertson S.J., Mitzel D.N., Park G.S., Boer E., Wolfinbarger J.B., and Bloom M.E. Inhibition of Interferon-Stimulated JAK-STAT Signaling by a Tick-Borne Flavivirus and Identification of NS5 as an Interferon Antagonist. J. Virol. 79 (2005) 12828-12839
10. Borowski P., Deinert J., Schalinski S., Bretner M., Ginalski K., Kulikowski T., and Shugar D. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur. J. Biochem. 270 (2003) 1645-1653
11. Broom A.K., Wallace M.J., Mackenzie J.S., Smith D.W., and Hall R.A. Immunisation with gamma globulin to murray valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against australian encephalitis: evaluation in a mouse model. J. Med. Virol. 61 (2000) 259-265
12. Buescher E.L., and Scherer W.F. Ecologic studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions. Am. J. Trop. Med. Hyg. 8 (1959) 719-722
13. Buescher E.L., Scherer W.F., Mc C.H., Moyer J.T., Rosenberg M.Z., Yoshii M., and Okada Y. Ecologic studies of Japanese encephalitis virus in Japan. IV. Avian infection. Am. J. Trop. Med. Hyg. 8 (1959) 678-688
14. Buescher E.L., Scherer W.F., Rosenberg M.Z., Gresser I., Hardy J.L., and Bullock H.R. Ecologic studies of Japanese encephalitis virus in Japan. II. Mosquito infection. Am. J. Trop. Med. Hyg. 8 (1959) 651-664
15. Burke D.S., and Monath T.P. Flaviviruses. In: Knippe D.M., and Howley P.M. (Eds). Fields Virology vol. 1 (2001), Lippincott Williams & Wilkins, London, New York, Tokyo 1043-1125
16. Caramello P., Canta F., Balbiano R., Lipani F., Ariaudo S., De Agostini M., Calleri G., Boglione L., and Di Caro A. Role of intravenous immunoglobulin administration in Japanese encephalitis. Clin. Infect. Dis. 43 (2006) 1620-1621 (Clin. Infect. Dis. v., 1620-1621)
17. Chang C.C., Ou Y.C., Raung S.L., and Chen C.J. Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection. J. Gen. Virol. 86 (2005) 2513-2523
18. Chanprapaph S., Saparpakorn P., Sangma C., Niyomrattanakit P., Hannongbua S., Angsuthanasombat C., and Katzenmeier G. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 330 (2005) 1237-1246
19. Chaturvedi U.C., Mathur A., Chandra A., Das S.K., Tandon H.O., and Singh U.K. Transplacental infection with Japanese encephalitis virus. J. Infect. Dis. 141 (1980) 712-715
20. Davis G.L. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin. Liver Dis. 19 Suppl. 1 (1999) 49-55
21. Davis G.L., Balart L.A., Schiff E.R., Lindsay K., Bodenheimer Jr. H.C., Perrillo R.P., Carey W., Jacobson I.M., Payne J., Dienstag J.L., et al. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multi-centre randomized, controlled trial. The Hepatitis Interventional Therapy Group. J. Hepatol. 11 Suppl 1 (1990) S31-S35
22. de Lamballerie X., Crochu S., Billoir F., Neyts J., de Micco P., Holmes E.C., and Gould E.A. Genome sequence analysis of Tamana bat virus and its relationship with the genus Flavivirus. J. Gen. Virol. 83 (2002) 2443-2454
23. Deas T.S., Binduga-Gajewska I., Tilgner M., Ren P., Stein D.A., Moulton H.M., Iversen P.L., Kauffman E.B., Kramer L.D., and Shi P.Y. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79 (2005) 4599-4609
24. Deas T.S., Bennett C.J., Jones S.A., Tilgner M., Ren P., Behr M.J., Stein D.A., Iversen P.L., Kramer L.D., Bernard K.A., and Shi P.Y. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51 (2007) 2470-2482
25. Dhanda V., Thenmozhi V., Hiriyan J., Arunachalam N., Balasubramanian A., Ilango A., and Gajanana A. Virus isolation from wild-caught mosquitoes during a Japanese encephalitis outbreak in Kerala in 1996. Indian J. Med. Res. 106 (1997) 4-6
26. Diamond M.S., Zachariah M., and Harris E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304 (2002) 211-221
27. Endy T.P., and Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr. Top. Microbiol. Immunol. 267 (2002) 11-48
28. Frick D.N., and Lam A.M.I. Understanding Helicases as a Means of Virus Control. Curr. Pharm. Design. 12 (2006) 1301-1314
29. Gilbert B.E., Wilson S.Z., Knight V., Couch R.B., Quarles J.M., Dure L., Hayes N., and Willis G. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Ch. 27 (1985) 309-313
30. Gish R.G. Standards of treatment in chronic hepatitis C. Semin. Liver Dis. 19 Suppl. 1 (1999) 35-47
31. Gonzalez-Peralta R.P., Galasso G.J., Poynard T., Schalm S., TH C., and Wright T.L. Summary of the first international symposium on viral hepatitis. Antivir. Res. 42 (1999) 77-96
32. Gould E.A., Buckley A., Barrett A.D., and Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol. 67 Pt 3 (1986) 591-595
33. Gould E.A., Buckley A., Groeger B.K., Cane P.A., and Doenhoff M. Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. J. Gen. Virol. 68 Pt 12 (1987) 3105-3112
34. Gould E.A., Moss S.R., and Turner S.L. Evolution and dispersal of encephalitic flaviviruses. Arch. Virol. Suppl. 18 (2004) 65-84
35. Gritsun T.S., and Gould E.A. Origin and evolution of 3'UTR of flaviviruses: long direct repeats as a basis for the formation of secondary structures and their significance for virus transmission. Adv Virus Res 69 (2007) 203-248
36. Gritsun T.S., and Gould E.A. Origin and evolution of flavivirus 5'UTRs and panhandles; trans-terminal duplications?. Virology 366 (2007) 8-15
37. Halstead S.B., and Grosz C.R. Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea. Am. J. Hyg. 75 (1962) 190-201
38. Hanna J.N., Ritchie S.A., Phillips D.A., Lee J.M., Hills S.L., van den Hurk A.F., Pyke A.T., Johansen C.A., and Mackenzie J.S. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170 (1999) 533-536
39. Hanna J.N., Ritchie S.A., Phillips D.A., Shield J., Bailey M.C., Mackenzie J.S., Poidinger M., McCall B.J., and Mills P.J. An outbreak of Japanese encephalitis in the Torres Strait, Australia 1995. Med. J. Aust. 165 (1996) 256-260
40. Harinasuta C., Nimmanitya S., and Titsyakorn U. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand SE Asian. J. Trop. Med. Public Health 16 (1985) 332-336
41. Hoke C.H., Nisalak A., Intralawan P., Poolsuppasit S., Jongsawas V., Titsyakorn U., Johnson R.T., and Vaughn D.W. Effect of high dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J. Infect. Dis. 165 (1992) 631-637
42. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Reviews of Infectious Diseases 11 Suppl. 4 (1989) 750-761
43. Huggins J.W., Robins R.K., and Canonico P.G. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob. Agents Ch. 26 (1984) 476-480
44. Huggins J.W., Kim G.R., Brand O.M., and McKee Jr. K.T. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153 (1986) 489-497
45. Huggins J.W., Hsiang C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., LeDuc J.W., Zheng Z.M., Meegan J.M., and Wang Q.N. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164 (1991) 1119-1127
46. Igarashi A. Control of Japanese encephalitis in Japan: immunization of humans and animals, and vector control. Curr. Top. Microbiol. Immunol. 267 (2002) 139-152
47. Igarashi A., Tanaka M., Morita K., Takasu T., Ahmed A., Ahmed A., Akram D., and Waqar M. Detection of West Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol. Immunol. 38 (1994) 827-830
48. Johansen C.A., van den Hurk A.F., Ritchie S.A., Zborowski P., Nisbet D.J., Paru R., Bockarie M.J., Macdonald J., Drew A.C., Khromykh T.I., and Mackenzie J.S. Isolation of Japanese encephalitis virus from mosquitoes (Diptera: Culicidae) collected in the Western Province of Papua New Guinea 1997-1998. Am. J. Trop. Med. Hyg. 62 (2000) 631-638
49. Kabilan L., Vrati S., Ramesh S., Srinivasan S., Appaiahgari M.B., Arunachalam N., Thenmozhi V., Kumaravel S.M., Samuel P.P., and Rajendran R. Japanese encephalitis virus (JEV) is an important cause of encephalitis among children in Cuddalore district, Tamil Nadu, India. J. Clin. Virol. 31 (2004) 153-159
50. Kimura Kuroda J., and Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141 (1988) 3606-3610
51. Kinney R.M., Huang C.Y., Rose B.C., Kroeker A.D., Dreher T.W., Iverson P.L., and Stein D.A. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J. Virol. 79 (2005) 5116-5128
52. Koff W.C., Pratt R.D., Elm J.J.L., Venkateshan C.N., and Halstead S.B. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob. Agents Ch. 24 (1983) 134-136
53. Kumar P., Lee S.K., Shankar P., and Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLos Med. 3 (2006) 0505-0514
54. Kumar P., Wu H., McBride J.L., Jung K.E., Hee K.M., Davidson B.L., Kyung L.S., Shankar P., and Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (2007) 39-43
55. Kunz C., Hofmann H., Kundi M., and Mayer K. Zur Wirksamkeit von FSME-immunglobulin. Wien. Klein. Wochenschr. 93 (1981) 665-667
56. Kuwayama M., Ito M., Takao S., Shimazu Y., Fukuda S., Miyazaki K., Kurane I., and Takasaki T. Japanese encephalitis virus in meningitis patients, Japan. Emerg. Infect. Dis. 11 (2005) 471-473
57. LaColla, P., Sommadossi, J.-P., 2004. US6812219.
58. Lau J.Y., Qian A., Detmer J., Collins M.L., Orito E., Kolberg Ja, Urdea M.S., Mizokami M., and Davis G.L. Effect of interferon-alpha and ribavirin therapy on serum GBV virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV. J. Infect. Dis. 176 (1997) 421-426
59. Leyssen P., Balzarini J., De Clercq E., and Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79 (2005) 1943-1947
60. Leyssen P., Van Lommel A., Drosten C., Schmitz H., De Clercq E., and Neyts J. A novel model for the study of the therapy of flavivirus infections using the Modoc virus. Virology 279 (2001) 27-37
61. Lin C., and Kim J.L. Structure-based mutagenesis study of hepatitis C virus NS3 helicase. J. Virol. 73 (1999) 8798-8807
62. Lindenbach B.D., and Rice C.M. Molecular biology of flaviviruses. Adv. Virus Res. 59 (2003) 23-47
63. Liu W.J., Chen H.B., Wang X.J., Huang H., and Khromykh A.A. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J. Virol. 78 (2004) 12225-12235
64. Lobigs M., Pavy M., and Hall R. Cross-protective and infection-enhancing immunity in mice vaccinated against flaviviruses belonging to the Japanese encephalitis virus serocomplex. Vaccine 21 (2003) 1572-1579
65. Lopez Labrador, F.X., Ampurdanes, S., Gimenez, B., M., Guilera, M., Costa, J., de Anta, M.T.J., Sanchez Tapiaz, J.M., Rodes, J., Saiz, J.C., 1999. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to inteferon in patients with chronic HCV genotype 1b. Hepatology 29, 897-903.
66. Mackenzie, J., 1997. Emerging viral diseases: an Australian and Papua New Guinean perspective. In: 33rd Annual symposium of the Medical Society of Papua New Guinea, p 12 Goroka.
67. Mackenzie J.S. Emerging zoonotic encephalitis viruses: lessons from Southeast Asia and Oceania. J. Neurovirol. 11 (2005) 434-440
68. Mackenzie J.M., Barrett A.D., and Deubel V. The Japanese encephalitis serological group of flaviviruses: a brief introduction to the group. In: Mackenzie J.M., et al. (Ed). Japanese Encephalitis and West Nile Viruses vol. 267 (2002), Springer-Verlag, Berlin, Heidelberg, New York 1-10
69. Mackenzie J.S., Johansen C.A., Ritchie S.A., van den Hurk A.F., and Hall R.A. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol 267 (2002) 49-73
70. Mackenzie J.S., Williams D.T., and Smith D.W. Japanese encephalitis virus: the geographic distribution incidence and spread of a virus with a propensity to emerge in new areas. Perspect. Med. Virol. 16 (2007) 201-268
71. Malinoski F.J., Hasty S.E., Ussery M.A., and Dalrymple J.M. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antivir. Res. 13 (1990) 139-149
72. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., and Williams R.B. Lassa fever effective therapy with ribavirin. N. Engl. J. Med. 314 (1986) 20-26
73. McCown M., Diamond M.S., and Pekosz A. The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. J. Virol. 313 (2003) 514-524
74. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman E.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339 (1998) 1485-1492
75. Migliaccio G., Tomassini J.E., Carroll S.S., Tomei L., Altamura S., Bhat B., Bartholomew L., Bosserman M.R., Ceccacci A., Colwell L.F., Cortese R., De Francesco R., Eldrup A.B., Getty K.L., Hou X.S., LaFemina R.L., Ludmerer S.W., MacCoss M., McMasters D.R., Stahlhut M.W., Olsen D.B., Hazuda D.J., and Flores O.A. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278 (2003) 49164-49170
76. Mitamura T., Kitaoka M., Mori K., Okubo K., and Tenjin T. Uber den Infektionsmodus der japanischen epidemischen Enzephalitis mit besonderer Berucksichtigung der experimentellen und epidemiologischen Beweise fur die Krankheitsiibertragung durch Mucken. Transactiones Societatis Pathologicae Japonicae 28 (1938) 135-145
77. Monath T.P. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol. 267 (2002) 105-138
78. Morrey J.D., Smee D.F., Sidwell R.W., and Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antivir. Res. 55 (2002) 107-116
79. Moulton H.M., Nelson M.H., Hatlevig S.A., Reddy M.T., and Iverson P.L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjugate Chem. 15 (2004) 290-299
80. Muñoz-Jordán J.L., Laurent-Rolle M., Ashour J., Martínez-Sobrido L., Ashok M., Lipkin W.I., and García-Sastre A. Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses. J. Virol. 79 (2005) 8004-8013
81. Murakami M., Ota T., Nukuzuma S., and Takegami T. Inhibitory effect of RNAi on Japanese encephalitis virus replication in vitro and in vivo. Microbiol. Immunol. 49 (2005) 1047-1056
82. Nakano A., Yamasaki R., Miyazaki S., Nobuaki H., Kunishige M., and Mitsui T. Beneficial effect of steroid pulse therapy on acute viral encephalitis. Eur. Neurol. 50 (2003) 225-229
83. Nall T.A., Chappell K.J., Stoermer M.J., Fang N.X., Tyndall J.D., Young P.R., and Fairlie D.P. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J. Biol. Chem. 279 (2004) 4853548542
84. Nam J.H., Chae S.L., Park S.H., Jeong Y.S., Joo M.S., Kang C.Y., and Cho H.W. High level of sequence variation in the 3' noncoding region of Japanese encephalitis viruses isolated in Korea. Virus Genes 24 (2002) 21-27
85. Neyts J., Meerbach A., McKenna P., and De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antivir. Res. 30 (1996) 125-132
86. Nothdurft H.D., Jelinek T., Marschang A., Maiwald H., Kapaun A., and Loscher T. Adverse reactions to Japanese encephalitis vaccine in travelers. J. Infection 32 (1996) 119-122
87. Okabe, N., Background of recent JE vaccine issues. Uirusu 55.2005.
88. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S.E.M.M., Marri K., Chung K.M., Ebel G.D., Kramer L.D., Fremont D.H., and Diamond M.S. Development of a humanized monoclonal antibody with therapeutic potential against West Nile Virus. Nat. Med. 11 (2005) 522-530
89. Olsen D.B., Eldrup A.B., Bartholomew L., Bhat B., Bosserman M.R., Ceccacci A., Colwell L.F., Fay J.F., Flores O.A., Getty K.L., Grobler J.A., LaFemina R.L., Markel E.J., Migliaccio G., Prhavc M., Stahlhut M.W., Tomassini J.E., MacCoss M., Hazuda D.J., and Carroll S.S. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Ch. 48 (2004) 3944-3953
90. Ono L., Wollinger W., Rocco I.M., Coimbra T.L., Gorin P.A., and Sierakowski M.R. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111strain) and dengue 1 virus (Hawaii strain). Antivir. Res. 60 (2003) 201-208
91. PATH, 2006. Historic protection for Asia's children: PATH and our partners take action to eliminate Japanese encephalitis. www.pathorg/projects/japanese_encephalitis_projectphp.
92. Pawlotsky J.M., Germanidis G., Neumann A.U., Pellerin M., Frainais P.O., and Dhumeaux D. Interferon resistance to of hepatitis C virus genotype 1b: relationship to nonstructural NS5 gene quasispecies mutations. J. Virol. 72 (1998) 2795-2805
93. Peignoux M.M., Boyer N., Pouteau M., Castelnau C., Giuily N., Duchatelle V., Auperin A., Degott C., BJ P., Ernlinger S., and Marcellin P. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 29 (1998) 214-223
94. Plesner A.M., Arlien-Soborg P., and Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 348 (1996) 202-203
95. Poidinger M., Hall R.A., and Mackenzie J.S. Molecular characterization of the Japanese encephalitis serocomplex of the flavivirus genus. Virology 218 (1996) 417-421
96. Prasad S.R., Kumar V., Marwaha R.K., Batra K.L., Rath R.K., and Pal S.R. An epidemic of encephalitis in Haryana: serological evidence of Japanese encephalitis in a few patients. Indian Pediatr. 30 (1993) 905-910
97. Rahal J.J., Anderson J., Rosenberg C., Reagan T., and Thompson L.L. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis clinical and laboratory results of a pilot study. J. Infect. Dis. 190 (2004) 1084-1087
98. Ray D., and Shi Y. Recent advances in flavivirus antiviral drug discovery and vaccine development. Recent Patents Anti-Infect. Drug Discov. 1 (2006) 45-55
99. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., and Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229 (1985) 726-733
100. Rostaing L., Izopet J., Moussion F., Alric L., Verdier D., That H.T., Duffaut M., Durand D., Puel J., and Suc J.M. HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C. Nephrologie 18 (1997) 281-286
101. Saxena S.K., Mathur A., and Srivastava R.C. Inhibition of Japanese encephalitis virus infection by diethyldithiocarbamate is independent of its antioxidant potential. Antivir. Chem. Chemoth. 14 (2003) 91-98
102. Sayao A.L., Suchowersky O., Al-Khathaami A., Klassen B., Katz N.R., Sevick R., Tilley P., Fox J., and Patry D. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can. J. Neurol. Sci. 31 (2004) 194-203
103. Sbrana E., Xiao S.Y., Guzman H., Ye M., Da Rosa A.P.A.T., and Tesh R.B. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am. J. Trop. Med. Hyg. 71 (2004) 306-312
104. Schiøler K., Samuel M., and Wai K.L. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst. Rev. 18 3 (2007) CD004263
105. Shigeta S., Mori S., Kodama E., Kodama J., Takahashi K., and Yamase T. Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antivir. Res. 58 (2003) 265-271
106. Shimoni Z., Niven M.J., Pitlick S., and Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg. Infect. Dis. 7 (2001) 759
107. Shlim D.R., and Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin. Infect. Dis. 35 (2002) 183-188
108. Sintchak M.D., Fleming M.A., Futer O., Raybuck S.A., Chambers S.P., Caron P.R., Murcko M.A., and Wilson K.P. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85 (1996) 921-930
109. Solomon T., and Vaughn D.W. Pathogenesis and Clinical Features of Japanese Encephalitis and West Nile Virus Infections (2002), Springer, Berlin
110. Solomon T., Kneen R., Dung N.M., Khanh V.C., Thuy T.T., Ha D.Q., Day N.P., Nisalak A., Vaughn D.W., and White N.J. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet 351 (1998) 1094-1097
111. Solomon T., Dung N.M., Kneen R., Gainsborough M., Vaughn D.W., and Khanh V.T. Neurological aspects of tropical disease: Japanese encephalitis. J. Neurol. Neurosurg. Psychiatry 68 (2000) 405-415
112. Solomon T., Dung N.M., Kneen R., Thao L.T.T., Gainsborough M., Nisalak A., Day N.P.J., Kirkham F.J., Vaughn D.W., Smith S., and White N.J. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 125 (2002) 1084-1093
113. Solomon T., Dung N.M., Wills B., Kneen R., Gainsborough M., Diet T.V., Thuy T.T., Loan H.T., Khanh V.C., Vaughn D.W., White N.J., and Farrar J.J. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 361 (2003) 821-826
114. Solomon T., Ni H., Beasley D.W., Ekkelenkamp M., Cardosa M.J., and Barrett A.D. Origin and evolution of Japanese encephalitis virus in southeast Asia. J. Virol. 77 (2003) 3091-3098
115. Stamos, D.P., Bethiel, R.S., 2004. US6825224.
116. Stein, D.A., Skilling, D.E., Iverson, P.L., Smith, A.W., 2004. US6828105.
117. Stephen E.L., Sammons M.L., Pannier W.L., Baron S., Spertzel R.O., and Levy H.B. Effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J. Infect. Dis. 136 (1977) 122-126
118. Summerton J., and Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic A. 7 (1997) 187-195
119. Taber L.H., Knight V., Gilbert B.E., McClung H.W., Wilson S.Z., Norton H.J., Thurson J.M., Gordon W.H., Atmar R.L., and Schlaudt W.R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72 (1983) 613-618
120. Takahashi H., Pool V., Tsai T.F., Chen R.T., and The VAERS Working Group. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. Vaccine 18 (2000) 2963-2969
121. Talarico L.B., Pujol C.A., Zibetti R.G., Faria P.C., Noseda M.D., Duarte M.E., and Damonte E.B. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cells. Antivir. Res. 66 (2005) 103-110
122. Thiel H.-J., Collett M.S., Gould E.A., Heinz F.X., Houghton M., Meyers G., Purcell R.H., and Rice C.M. Flaviviridae. In: Fauquet C.M., et al. (Eds). Virus Taxonomy: VIIIth Report of the ICTV (2005), Elsevier/Academic Press, London 981-998
123. Tsai, T.F., 2000. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998; Vaccine 18 (Suppl 2) 1-25.
124. Twiddy S.S., and Holmes E.C. The extent of homologous recombination in members of the genus Flavivirus. J. Gen. Virol. 84 (2003) 429-440
125. Uchil P.D., and Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering and multiple introductions of the virus into the Indian subcontinent. Am. J. Trop. Med. Hyg. 65 (2001) 242-251
126. Umenai T., Krzysko R., Bektimirov T.A., and Assaad F.A. Japanese encephalitis: current worldwide status. Bull World Health Organ 63 (1985) 625-631
127. Vaughn D.W., and Hoke C.H. The epidemiology of Japanese encephalitis: Prospects for prevention. Epidem. Rev. 14 (1992) 197-221
128. Vithanomsat S., Wasi C., Harinasuta C., and Thongcharoen P. The effect of interferon on flaviviruses in vitro: a preliminary study. SEAsian J. Trop. Med. Public Health. 15 (1984) 27-31
129. WHO. Global AdvisoryCommittee onVaccine Safety. Wkly. Epidemiol. Rec. 80 (2005) 242-243
130. WHO. Japanese encephalitis vaccines. WHO position paper. Wkly. Epidemiol. Rec. 73 (1998) 337-344
131. Wittesjö B., Eitrem R., Niklasson B., Vene S., and Mangiafico J.A. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345 (1995) 856
132. Yang G., Caroli Bosc F.X., Laffont C., Bianchi D., Dantin S., Lefebvre J.C., and Doglio A. Hepatitis G and C viruses respond to interferon-alpha with different virologic kinetics. Dig. Dis. Sci. 43 (1998) 1307-1310
133. Zhang N., Chen H.M., Koch V., Schmitz H., Liao C.L., Bretner M.M., Bhadti V.S., Fattom A.I., Naso R.B., Hosmane R.S., and Borowski P. Ring-expanded nucleoside and nucleotide (REN) analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J. Med. Chem. 46 (2003) 4149-4164
134. Zhang N., Chen H.M., Koch V., Schmitz H., Minczuk M., Stepien P., Fattom A.I., Naso R.B., Kalicharran K., Borowski P., and Hosmane R.S. Potent inhibition of NTPase/helicase of the West Nile Virus by ring-expanded ("fat") nucleoside analogues. J. Med. Chem. 46 (2003) 4776-4789